Abraxane: Clinical Trials

285 trials of Abraxane, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

129 completed, 51 terminated, 32 recruiting, 28 unknown. 285 Phase 2, 65 Phase 1, 7 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2285Completed 129, Terminated 51, Recruiting 32, Unknown 28, Active not recruiting 26, Withdrawn 15, Not yet recruiting 4
Phase 165Completed 32, Terminated 15, Recruiting 7, Unknown 4, Withdrawn 4, Active not recruiting 3
Phase 37Active not recruiting 2, Recruiting 2, Completed 1, Unknown 1, Withdrawn 1

Follow Abraxane: new trials by email Literature Review of Abraxane trials Research Report on Abraxane

Trials (filtered) newest first · largest first

All 285 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC
certepetide, nab-paclitaxel, gemcitabine - Pancreas Cancer, Pancreatic Carcinoma
Phase 1 / Phase 2WithdrawnLisata Therapeutics, Inc.2030-01-012025-06-06
Aspirin and PAClitaxel in Head & Neck Squamous Cell Carcinoma
Aspirin, Paclitaxel - Head and Neck (HNSCC), Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
Phase 2Not yet recruitingWashington University School of Medicine402026-12-312026-10-28
SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial
Biospecimen Collection, Computed Tomography, Electronic Health Record Review - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Phase 2RecruitingNorthwestern University1252026-10-262026-10-29
DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer
Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging - Borderline Resectable Pancreatic Ductal Adenocarcinoma
Phase 1 / Phase 2RecruitingOhio State University Comprehensive Cancer Center502026-10-012026-10-05
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Navlimetostat, Daraxonrasib, Temozolomide - Solid Tumors
Phase 2RecruitingBristol-Myers Squibb2542026-07-272026-11-04
Window of Opportunity in Preserving Laryngeal Function Trial
Toripalimab, Carboplatin, Cisplatin - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma
Phase 2RecruitingMatthew Spector872026-04-062026-10-16
ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma
ONT01, Gemcitabine, Nab paclitaxel - Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1 / Phase 2RecruitingWashington University School of Medicine612026-03-252026-05-19
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma
Phase 2RecruitingMayo Clinic432025-12-122026-10-02
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Navlimetostat, Gemcitabine, Nab-paclitaxel - Pancreatic Ductal Adenocarcinoma
Phase 2 / Phase 3Active not recruitingBristol-Myers Squibb4702025-10-232026-06-03
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
Cisplatin, Carboplatin, Pemetrexed - Non-small Cell Lung Cancer
Phase 2RecruitingH. Lee Moffitt Cancer Center and Research Institute3182025-06-132026-09-21
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Pembrolizumab, Carboplatin, Paclitaxel - Non-small Cell Lung Cancer
Phase 2RecruitingMerck Sharp & Dohme LLC902025-03-302026-10-16
Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer
sintilimab, nab-paclitaxel, gemcitabine - Pancreatic Cancer, Stage IB, Pancreatic Cancer, Stage IIA
Phase 2Not yet recruitingShanghai Zhongshan Hospital502025-03-202025-01-22
Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer
Nab paclitaxel, Gemcitabine, TheraBionic P1 - Metastatic Pancreatic Adenocarcinoma
Phase 2RecruitingBarbara Ann Karmanos Cancer Institute302025-02-282026-08-10
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
Gemcitabine, Nab paclitaxel, Erlotinib - Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
Phase 1 / Phase 2RecruitingUNC Lineberger Comprehensive Cancer Center1042025-02-062026-04-23
Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard Therapy
Abraxane, Nedaplatin - Hepatic Artery Infusion, Liver Metastasis of Breast Cancer
Phase 2RecruitingZhejiang Cancer Hospital302025-02-012025-12-16
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine - Rare Tumour
Phase 2Not yet recruitingPeking University Shenzhen Hospital2002025-01-012024-11-18
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
Sintilimab, Abraxane, Carboplatin - Triple Negative Breast Cancer (TNBC)
Phase 2RecruitingThe First Affiliated Hospital with Nanjing Medical University582025-01-012026-05-15
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
Pembrolizumab, Paclitaxel, Carboplatin - Anal Cancer
Phase 2RecruitingDustin Deming232024-09-302026-11-05
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
Nab paclitaxel, Gemcitabine, Cisplatin - Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma
Phase 2 / Phase 3Active not recruitingAlliance for Clinical Trials in Oncology102024-08-132026-10-19
AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC
AGEN1423, Botensilimab, Gemcitabine - Advanced Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Phase 2Active not recruitingBruno Bockorny242024-08-082026-07-09

Showing 20 of 285. Sign in to see all of them.

Conditions studied

Pancreatic Neoplasms (74)  ·  Breast Neoplasms (57)  ·  Carcinoma, Non-Small-Cell Lung (24)  ·  Neoplasm Metastasis (20)  ·  Neoplasms (20)  ·  Triple Negative Breast Neoplasms (18)  ·  Lung Neoplasms (15)  ·  Squamous Cell Carcinoma of Head and Neck (12)  ·  Recurrence (9)  ·  Head and Neck Neoplasms (8)  ·  Melanoma (8)  ·  Ovarian Neoplasms (8)  ·  Sarcoma (8)  ·  Adenocarcinoma (6)  ·  Cholangiocarcinoma (6)

Sponsors

M.D. Anderson Cancer Center (10)  ·  Celgene (9)  ·  Washington University School of Medicine (9)  ·  UNC Lineberger Comprehensive Cancer Center (6)  ·  Columbia University (5)  ·  Mayo Clinic (5)  ·  SCRI Development Innovations, LLC (5)  ·  Abramson Cancer Center at Penn Medicine (4)  ·  Emory University (4)  ·  NYU Langone Health (4)  ·  National Cancer Institute (NCI) (4)  ·  OHSU Knight Cancer Institute (4)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4)  ·  Bristol-Myers Squibb (3)  ·  Chinese PLA General Hospital (3)

Countries

United States (202)  ·  China (30)  ·  Italy (22)  ·  Spain (21)  ·  Canada (19)  ·  Germany (19)  ·  France (16)  ·  United Kingdom (15)  ·  Australia (11)  ·  South Korea (9)  ·  Switzerland (9)  ·  Belgium (8)  ·  Taiwan (8)  ·  Japan (7)  ·  Netherlands (6)

Top investigators

Jared Weiss, MD (4)  ·  Douglas Adkins, M.D. (3)  ·  Charles D Lopez (2)  ·  Douglas R Adkins, M.D. (2)  ·  Dung Le, MD (2)  ·  Ileana Elias, M.D. (2)  ·  Jenny C Chang, MD (2)  ·  John Hainsworth, MD (2)  ·  Mitsuhiko Iwamoto, MD, PhD (2)  ·  Mustafa Khasraw, MD (2)  ·  Peter O'Dwyer, MD (2)  ·  A P Chen (1)

Results publications

PMID 31401903, PMID 28797458, PMID 30998813, PMID 11698646, PMID 15030777, PMID 15240681, PMID 15358536, PMID 15771580, PMID 15800326, PMID 16227604, PMID 18565862, PMID 19426218, PMID 20516428, PMID 20530281, PMID 20585851, PMID 20625120, PMID 20636820, PMID 20658263, PMID 20705560, PMID 21976055, PMID 22307213, PMID 22960352, PMID 23659317, PMID 23706985, PMID 24013936, PMID 24318901, PMID 24327518, PMID 24422706, PMID 24703985, PMID 25579459, PMID 25616430, PMID 25845992, PMID 26445094, PMID 27078022, PMID 27404453, PMID 27424289, PMID 27701653, PMID 27718847, PMID 27745820, PMID 28053024, PMID 28114604, PMID 28238593, PMID 28271869, PMID 28303530, PMID 28397697, PMID 28397821, PMID 28672195, PMID 28701571, PMID 28869790, PMID 28885881

NIH funding

2016 (4), P30CA015083 (3), P30CA138292 (3), U10CA180820 (3), 2025 (2), P30CA068485 (2), U10CA027469 (2), 2014 (1), 2015 (1), 2017 (1), 2023 (1), P01CA217797 (1), P30CA015704 (1), P30CA016059 (1), P30CA022453 (1)